Secondary progressive multiple sclerosis

8 trials 3 recruiting MedDRA PT
8 Registered trials
3 Recruiting
7 Unique sponsors
19 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
L Oncology (ATC L) 5
A Gastroenterology (ATC A) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 9 substances
BTK inhibitor 2 substances
Interferon 2 substances
Monoclonal antibody (immune, humanized) 2 substances
CAR-T cell therapy 1 substance
Monoclonal antibody (human) 1 substance
Antimetabolite 1 substance
Monoclonal antibody (chimeric) 1 substance
Phase III: 5 Phase II: 2 Phase I/II: 1

Filter these 8 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 8 trials

Phase III

5 trials
  • Novartis Pharma AG Commercial
    REMIBRUTINIB
    2025-521546-23-00 23 countries 2026 n=647
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    TERIFLUNOMIDE; TOLEBRUTINIB
    2023-503631-18-01 23 countries 2024 n=1,405
    Recruiting
  • Sanofi-Aventis Research & Development Commercial
    TERIFLUNOMIDE; TOLEBRUTINIB
    2023-503631-18-00 2 countries n=75
    Not authorised
  • Centre Hospitalier Universitaire De Nantes Academic
    IMP not specified
    2024-516628-32-00 1 country 2019 n=250
    Ended
  • Rigshospitalet Academic
    OCRELIZUMAB; RITUXIMAB
    2024-514287-84-00 1 country 2021 n=600
    Ended

Phase II

2 trials
  • Antwerp University Hospital Academic
    DIMETHYL FUMARATE; FINGOLIMOD; GLATIRAMER ACETATE; INTERFERON BETA-1A; METFORMIN HYDROCHLORIDE; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB; OZANIMOD; PEGINTERFERON BETA-1A; PONESIMOD; RECOMBINANT INTERFERON BETA-1B; SIPONIMOD; TERIFLUNOMIDE
    2023-503190-38-00 1 country 2023 n=120
    Ended
  • Instytut Psychiatrii I Neurologii Academic
    CLADRIBINE
    2024-516992-33-02 1 country 2025 n=188
    Ended

Phase I/II

1 trial
  • Novartis Pharma AG Commercial
    RAPCABTAGENE AUTOLEUCEL
    2024-514006-31-00 4 countries 2026 n=18
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 2 Phase III, Phase I/II 2
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase III 1
Sanofi-Aventis Research & Development Commercial 1 Phase III 0
Antwerp University Hospital Academic 1 Phase II 0
Instytut Psychiatrii I Neurologii Academic 1 Phase II 0
Centre Hospitalier Universitaire De Nantes Academic 1 Phase III 0
Rigshospitalet Academic 1 Phase III 0
New trials by year
2019
1
2021
1
2023
1
2024
1
2025
1
2026
2
← All indication landscapes